Prime Secures Arbitration Victory Over Beam, Paving Way for Clinical Trials

Prime, a biotech firm developing a gene‑therapy candidate, won an arbitration case against Beam Therapeutics. The ruling removes a legal hurdle and allows Prime to advance its program into clinical testing.

The win arrives amid a wave of biotech headlines, including a major trial failure reported by AstraZeneca and Ionis, and a White House push to increase domestic drug manufacturing.

Industry observers view the arbitration outcome as a positive development for Prime, potentially accelerating timelines for patients who could benefit from the therapy.